EN3348's day will come...Below is a link to the "2011 Report: Medicines in Development for Cancer" presented by America's Biopharmaceutical Research Companies.
As you will read, there are 14 medicines in development for bladder cancer (currently in either clincal trials or under FDA review as defined by the report). However,
only two have reached phase 3 development status as of the release of this report (see pg 2 of report/link).
The two are (in alphabetical order):
Product Name Sponsor Indication Development Status
1) apaziquone* Allergan/ Spectrum Pharma non-invasive bladder cancer Phase III
(Fast Track)
2) EN3348** Endo Pharmaceuticals No indication provided but Phase III
designated as (Fast Track)
* as you recall apaziquone is a chemotherapy treatment (Mitomycin C Pro-drug)
** as an investor in Bioniche you know EN3348 is MCC trademarked Urocidin as a bladder cancer treatment.
For many others I guess EN3348 is a bladder cancer treatment in Ph III trials sponsored by Endo Pharmaceutical.
And, I will add, at an estimated cost of $60+ million to complete the current trial and totally funded by Endo.
Maybe Endo will tell the world just a little more about the Ph IIIb progress of EN3348/Urocidin in this morning's webcast presentation at the Stifel Nicolaus Annual Healthcare Conference (11:30am ET). Would be appreciated by long-standing/enduring Bioniche investors. rg